Repligen Corporation RGEN announced today that it has entered
into an exclusive worldwide licensing agreement with Pfizer PFE to
advance Repligen's spinal muscular atrophy (SMA) program, originally
in-licensed from Families of SMA (FSMA). The SMA program includes
RG3039, a small molecule drug candidate in clinical development for SMA,
as well as backup compounds and enabling technologies. Under the terms
of the agreement, Repligen is entitled to receive up to $70 million from
Pfizer, commencing with an upfront payment of $5 million and total
potential future milestone payments of up to $65 million as well as
royalties on any future sales of SMA compounds developed under the
agreement. SMA is an orphan neurodegenerative genetic disease that
presents early in life.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in